Ceres delays its IPO, slashes price
Thousand Oaks-based energy crop maker Ceres has drastically lowered expectations for its initial public offering and delayed it for a week, according to regulatory filings and investment banking sources. The company was set to raise as much as $132 million on the Nasdaq when shares hit the markets under the name CERE on Feb. 9. Read More →
Ceres set to sprout: Crop firm names date for $132M IPO
Ceres plans to go public on Feb. 9, raising as much as $132 million on the Nasdaq under the symbol CERE.
End of redevelopment challenges cities to focus on new ways to grow
The sudden demise of California’s redevelopment agencies continues to send shock waves across the Tri-Counties.
Inphi taps new CEO after profits fall 93%
Inphi Corp., the Santa Clara-based chip firm with a large engineering force in Thousand Oaks, ousted its CEO on Feb. 1 as it announced that profits plummeted by 93 percent in 2011. Inphi designs chips aimed at packing more memory into Internet servers and increasing bandwidth in the Internet backbone. The company announced that Ford Read More →
Ceres to debut at $21 to $23 per share
Thousand Oaks-based energy crop developer Ceres has plans to make its debut on the Nasdaq on Feb. 8 under the symbol CERE and raise $132 million. Shares in the company, which uses genetic marking technology to speed the development of non-food energy crops such as drought-resistant switchgrass, are expected hit the markets at between $21 Read More →
Amgen Q4 earnings drop 8.5%
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”26-07-2011″ enddate=”26-01-2012″ width=”300″ height=”245″] Biotech giant Amgen, which said earlier on Thursday that it would pay $1.2 billion for leukemia drugmaker Micromet, reported fourth-quarter earnings that missed analyst expectations. The Thousand Oaks-based company said fourth-quarter profits fell 8.5 percent to $934 million, or $1.08 per share, on lower sales of Read More →
